Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide add-on to sulfonylurea in HNF1A/HNF4A-MODY (MM-SEMA)
2025-523414-89-00Phase 2Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in maturity-onset diabetes of the young type 3 and Maturity Onset Diabetes of the Young (MODY) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Mean sensor glucose. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
maturity-onset diabetes of the young type 3Maturity Onset Diabetes of the Young (MODY)
Beyond the preview
Go deeper on 2025-523414-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523414-89-00.